Actos Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Upcoming Conference in Federal Actos Bladder Cancer Litigation

Share Article

The Firm is currently offering confidential Actos lawsuit evaluations to patients who may have developed bladder cancer, allegedly due to long-term use of the diabetes drug.

Free Case Review
We are pleased to see this litigation moving forward, as we continue to hear from Actos users who are concerned that this drug may have caused their bladder cancer diagnosis.

Actos lawsuits (http://www.consumerinjurylawyers.com/actos/Actos-Lawsuit.html) continue to move forward in the multidistrict litigation underway in U.S. District Court, Western District of Louisiana, Bernstein Liebhard LLP reports. According to court records, the proceeding’s next Case Management Conference is scheduled for August 22nd at 10:30 a.m. According to an August 15th update from the U.S. Judicial Panel on Multidistrict Litigation (JPML), more than 2,500 Actos bladder cancer lawsuits are currently pending in the federal litigation. (In re: Actos Product Liability Litigation, MDL No. 2299)

“We are pleased to see this litigation moving forward, as we continue to hear from Actos users who are concerned that this drug may have caused their bladder cancer diagnosis,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free Actos bladder cancer lawsuit evaluations to patients who developed the disease after using the medication for an extended period of time.

Actos Bladder Cancer
Actos lawsuits have been mounting since June 2011, when the U.S. Food & Drug Administration (FDA) warned that use of Actos for one year or more had been linked to the development of bladder cancer. All of the lawsuits pending in the Western District of Louisiana accuse Takeda Pharmaceuticals of concealing knowledge that use of the type 2 diabetes treatment was associated with an increased risk of bladder cancer, and failing to provide adequate warnings to patients and doctors regarding this risk. According to court documents, the first trial in the federal Actos bladder cancer litigation is scheduled to begin on January 27, 2014.

One state trial of an Actos lawsuit already concluded this April, when a Los Angeles Superior Court jury awarded $6.5 million to a plaintiff who was diagnosed with bladder cancer after taking Actos for four years. However, the judge overseeing the case granted Takeda Pharmaceuticals’ request to set aside the verdict. (Cooper v. Takeda Pharmaceuticals America Inc., CGC-12-518535, California Superior Court)

Long-term users of Actos who developed bladder cancer may be entitled to compensation for medical expenses, lost wages, pain and suffering, and more. Learn More about filing an Actos bladder cancer lawsuit by visiting Bernstein Liebhard LLP’s website. For additional information, please contact Bernstein Liebhard LLP today by calling 800-511-5092.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
###

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info(at)consumerinjurylawyers(dot)com
http://www.consumerinjurylawyers.com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Felecia L. Stern
Follow us on
Visit website